Jan 23 2026

george

Meta-analysis: D-dimer Safely Excludes Pulmonary Embolism in Cancer

Obtain this provocative article from your medical library: Vrotniakaite-Bajerciene K, Mallick R, Takada T, et al. Safety and efficiency of D-dimer testing in combination with clinical decision rules to exclude pulmonary embolism in patients with cancer: individual patient data meta-analysis. J Thromb Haemost. 2025:S1538-7836(25)00839-6. doi: 10.1016/j.jtha.2025.10.035. PMID: 41354153. Abstract Background: Failure rates of clinical decision […]

read more

Comments (0)

Thrombophilia

Jan 14 2026

george

Pilot Study: Oxerutin Therapy for Post-thrombotic Syndrome

Select this link to an open-access pilot study describing oxerutin, which is designed to reduce venous blockage after DVT: Iding AFJ, Hupperetz RD, Brans RJB, et al. Additional oxerutin therapy to promote deep vein thrombus resolution (RESOLVE-DVT): a randomized controlled pilot trial. J Thromb Haemost. 2025:S1538-7836(25)00718-4. doi: 10.1016/j.jtha.2025.10.018. PMID: 41197809. Abstract Background: Postthrombotic syndrome (PTS) […]

read more

Comments (0)

Thrombophilia

Dec 30 2025

george

December 2025 QQ Results: Control Proteins

Our December 2025 Quick Question was a quiz that asked, “What plasma control protein acts against FIIa & FXa?” Here’s how our 34 respondents fared… Antithrombin: 27 (79%) Protein C: 5 (15%) Protein S: 1 (3%) Protein Z: 0 TFPI: 1 (3%) We scored well on this question. Antithrombin (AT), when activated by therapeutic heparin […]

read more

Comments (0)

Coagulation Factors

Dec 27 2025

george

Clinical Research Study: Andexanet Alfa for Enoxaparin Reversal

Navigate to this open-access article describing andexanet alfa reversal of LMWH: van Haaps TF, Benz AP, Xu L, Middeldorp S, Eikelboom JW, et al. Andexanet alfa for the reversal of the low-molecular-weight heparin enoxaparin. Res Pract Thromb Haemost. 2025;9:103191. doi: 10.1016/j.rpth.2025.103191. PMID: 41141842; PMCID: PMC12552982. Abstract Background Andexanet alfa (andexanet) is the only approved reversal […]

read more

Comments (1)

Anticoagulant Therapy

Dec 26 2025

george

Analytical Dilemmas in Lupus Anticoagulant Testing

Click here to read an open-access review by Moore GW. Analytical Dilemmas in Lupus Anticoagulant Testing. Explor Immunol. 2023;3:300–24 DOI: https://doi.org/10.37349/ei.2023.00104 Abstract Accurate lupus anticoagulant (LA) detection is crucial to antiphospholipid syndrome (APS) diagnosis. Detection is based on LA functional behavior in coagulation assays irrespective of epitope specificity. LA screening tests employ dilute phospholipids to […]

read more

Comments (0)

Arterial Thrombosis

Dec 15 2025

george

Discussion of Phase I Data on a Unique anti-VWF Thrombolytic

A summary by Dr. Wolfgang Miesbach: A potential landmark thrombolytic innovation presented at ASH 2025. Thrilled by the exciting Phase 1 data presentation by Marie Scully and co-authors on TGD001, a groundbreaking novel von Willebrand factor (VWF)-targeting thrombolytic: First-of-its-kind mechanism: TGD001 is an antibody-enzyme fusion protein—specifically, an anti-VWF antibody fragment fused to a urokinase catalytic domain. […]

read more

Comments (0)

Arterial Thrombosis

Dec 15 2025

george

Editorial: Thrombophilia Diagnosis–Genetic or Functional Testing

Check with your medical library for Favaloro EJ, Moore GW, Pasalic L. Diagnosing thrombophilia: the case for genetic or functional testing? Expert Rev Mol Diagn. 2025:1-6. doi: 10.1080/14737159.2025.2588621. PMID: 41211955. Introduction The term thrombophilia defines a condition in which there is an elevated risk of thrombosis, usually venous thromboembolism (VTE), generally encompassing deep vein thrombosis […]

read more

Comments (0)

Thrombophilia

Dec 11 2025

george

Thrombotic Thrombocytopenic Purpura Sequelae

An ASH ’25 summary by Dr. Wolfgang Miesbach: iTTP remission ≠ cure–the vascular injury persists. TTP as a cardiovascular disease equivalent. I just finished Dr. Senthil Sukumar’s session on long-term iTTP management. This completely changed how I think about these patients, as illustrated: 28.6% of survivors → major cardiovascular events 50% → silent cerebral infarcts (vs […]

read more

Comments (0)

Thrombophilia

Dec 8 2025

george

A Coag Conversation: Alternate Warfarin Monitoring When the Prothrombin Time is Unreliable – Part 3: DOACs and Warfarin

Join me (Geo) and guest speaker Dr. Nicole Zantek, MD, PhD, Medical Director of the Special Coagulation Laboratory and Professor, Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, as we discuss the pathophysiology of antiphospholipid antibodies and alternative methods to monitor warfarin and DOAC anticoagulation in patients diagnosed with APS. Click DOACs […]

read more

Comments (1)

Anticoagulant Therapy

Nov 26 2025

george

Response to Low PS Inquiry on Diverse Health Hub

This question was posted on the Diverse Health Hub site (AKA Diagnostic Equity): “Can my birth control pills explain why my protein S level is low at 55%? OR…. should I be evaluated for an actual clotting disorder since low protein S runs in my family?” This comprehensive response was provided by my colleague, LaShanta […]

read more

Comments (0)

Thrombophilia